Answers are grounded in this paper and cite their sources.
Development of a new, sensitive immunoassay for measuring transforming growth factor beta 1 (TGF-β1) is described and compared with four commercially available TGF-β1 immunoassays. Preanalytical conditions were evaluated. The nonlinearity found in serum or plasma is due to masking of TGF-β1 by binding proteins in blood. Mixing TGF-β1 with latency-associated peptide or α2-macroglobulin at physiological concentrations suppressed most of the TGF-β1 signal. Plasma fibronectin showed no effect, even at concentrations exceeding its physiological range. Equilibrium concentrations computed from a model system confirmed the experimental results. Dilutional nonlinearity could be markedly reduced by an appropriately designed activation procedure that minimized the effects of reassociation between TGF-β1 and its binding partners during restoration of a neutral pH. Plasma should be used for measuring TGF-β1 in blood. Because serum TGF-β1 is highly significantly correlated with the platelet count, probably most of the TGF-β1 is released by platelet degranulation.
No takes yet. Share an insight, caveat, or question.
Kropf et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: